Healthcare / BiotechnologyNasdaqGM
$15.07
-0.24 (-1.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $44.1M · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
65/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.9B
P/E
7.0x
↓EV/EBITDA
15.1x
↑ROE
49.4%
↑Gross Margin
88.5%
↑Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
+150.1%
FCF CAGR
—
FCF margin
47.8%
FCF / Net income
0.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $283.1M · net income $287.2M · FCF $135.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $283.1M | $283.1M | $235.1M | $175.5M | $134.0M | $45.6M | $50.1M | $318000.00 | $463000.00 |
| Net Income | $287.2M | $287.2M | $5.8M | $-78.0M | $-108.2M | $-181.0M | $-102.7M | $-88.4M | $-53.1M |
| EBITDA | $137.9M | $137.9M | $31.7M | $-63.0M | $-103.6M | $-178.0M | $-102.9M | — | — |
| EPS | 2.07 | 2.07 | 0.04 | -0.54 | -0.76 | -1.40 | -0.87 | -0.95 | — |
| Gross Margin | 88.5% | 88.5% | 88.0% | 91.9% | 95.8% | — | — | — | — |
| Operating Margin | 37.6% | 37.6% | 7.8% | -52.2% | -83.2% | -396.3% | -208.1% | -28598.4% | -11930.9% |
| Net Margin | 101.5% | 101.5% | 2.4% | -44.5% | -80.7% | -396.8% | -204.9% | -27794.0% | -11464.1% |
| Balance Sheet | |||||||||
| Debt/Equity | 0.13 | 0.13 | 0.21 | 0.26 | 0.02 | — | — | — | — |
| Current Ratio | 5.55 | 5.55 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $135.4M | $135.4M | $44.1M | $-34.2M | $-79.8M | — | — | — | — |
| Returns | |||||||||
| ROE | 49.4% | 49.4% | 1.5% | -20.6% | -26.7% | -37.8% | -25.2% | -29.6% | -39.1% |
| Valuation | |||||||||
| P/E | 6.98 | 6.98 | 213.50 | — | — | — | — | — | — |
| EV/EBITDA | 15.11 | 15.11 | 39.22 | — | — | — | — | — | — |
| P/B | 3.60 | 3.60 | 3.31 | 3.18 | 2.64 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | 20.4% | 20.4% | 34.0% | 31.0% | — | -9.0% | 15660.4% | -31.3% | — |
| EPS Growth | 5075.0% | 5075.0% | 107.4% | 28.9% | — | -60.9% | 8.4% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-13.6%
EPS terminal req.
$1.34
Spread vs growth
5088.6%
5Y implied EPS CAGR
-4.8%
EPS terminal req.
$1.62
Spread vs growth
5079.8%
10Y implied EPS CAGR
2.3%
EPS terminal req.
$2.61
Spread vs growth
5072.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+89.3%
Start / end P/E
199.0x → 7.3x
EPS bridge
0.04 → 2.07
Residual
-4889.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.